Treatment of Pancreatic Cancer Bakersfield CA

Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say. Pancreatic cancer is resistant to every currently available anti-cancer treatment.

Bruce C Stone
(661) 631-5686
1524 27th St
Bakersfield, CA
Specialty
Urology

Data Provided by:
Robert L Waguespack
(661) 331-3303
3550 Q St Ste 302
Bakersfield, CA
Specialty
Urology

Data Provided by:
Robert Louis Waguespack, MD
(661) 321-3303
2201 19th St
Bakersfield, CA
Specialties
Urology
Gender
Male
Education
Medical School: Creighton Univ Sch Of Med, Omaha Ne 68178
Graduation Year: 1989

Data Provided by:
Dr.Robert L. Waguespack
(661) 331-3303
Apt B, 2530 F Street
Bakersfield, CA
Gender
M
Education
Medical School: Creighton Univ Sch Of Med
Year of Graduation: 1989
Speciality
Urologist
General Information
Accepting New Patients: Yes
RateMD Rating
2.9, out of 5 based on 5, reviews.

Data Provided by:
Joseph H Chang, MD
(661) 325-3937
4101 Empire Dr Ste 120
Bakersfield, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Ca, Irvine, Ca Coll Of Med, Irvine Ca 92717
Graduation Year: 1999

Data Provided by:
Shabbir Shakir, MD
(661) 395-0688
2808 F St Ste E
Bakersfield, CA
Specialties
Urology
Gender
Male
Education
Medical School: Grant Med Coll, Univ Of Bombay, Bombay, Maharashtra, India
Graduation Year: 1974

Data Provided by:
Bruce C Stone, DO
(661) 631-5686
1524 27th St Ste 200
Bakersfield, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Hlth Sci, Coll Of Osteo Med, Kansas City Mo 64124
Graduation Year: 1979

Data Provided by:
Shabbir Abdulkader Shakir
(661) 395-0688
2808 F St
Bakersfield, CA
Specialty
Urology

Data Provided by:
Peter R Mallen, MD FACS
(808) 245-1500
PO Box 12099
Bakersfield, CA
Gender
Male
Education
Medical School: Alberta
Graduation Year: 1963

Data Provided by:
Bruce Jay Joseph, MD
(661) 323-6660
6001 Truxtun Ave Ste 220
Bakersfield, CA
Specialties
Urology
Gender
Male
Education
Medical School: Finch U Of Hs/Chicago Med Sch, North Chicago Il 60664
Graduation Year: 1974

Data Provided by:
Data Provided by:

Treatment of Pancreatic Cancer

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.

SOURCE: European Cancer Organization, news release, Sept. 24, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com